291 related articles for article (PubMed ID: 32151633)
1. Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
Boukalova S; Hubackova S; Milosevic M; Ezrova Z; Neuzil J; Rohlena J
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165759. PubMed ID: 32151633
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial ubiquinol oxidation is necessary for tumour growth.
Martínez-Reyes I; Cardona LR; Kong H; Vasan K; McElroy GS; Werner M; Kihshen H; Reczek CR; Weinberg SE; Gao P; Steinert EM; Piseaux R; Budinger GRS; Chandel NS
Nature; 2020 Sep; 585(7824):288-292. PubMed ID: 32641834
[TBL] [Abstract][Full Text] [Related]
3. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
4. Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction.
Fang J; Uchiumi T; Yagi M; Matsumoto S; Amamoto R; Takazaki S; Yamaza H; Nonaka K; Kang D
Biosci Rep; 2013 Feb; 33(2):e00021. PubMed ID: 23216091
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Bajzikova M; Kovarova J; Coelho AR; Boukalova S; Oh S; Rohlenova K; Svec D; Hubackova S; Endaya B; Judasova K; Bezawork-Geleta A; Kluckova K; Chatre L; Zobalova R; Novakova A; Vanova K; Ezrova Z; Maghzal GJ; Magalhaes Novais S; Olsinova M; Krobova L; An YJ; Davidova E; Nahacka Z; Sobol M; Cunha-Oliveira T; Sandoval-Acuña C; Strnad H; Zhang T; Huynh T; Serafim TL; Hozak P; Sardao VA; Koopman WJH; Ricchetti M; Oliveira PJ; Kolar F; Kubista M; Truksa J; Dvorakova-Hortova K; Pacak K; Gurlich R; Stocker R; Zhou Y; Berridge MV; Park S; Dong L; Rohlena J; Neuzil J
Cell Metab; 2019 Feb; 29(2):399-416.e10. PubMed ID: 30449682
[TBL] [Abstract][Full Text] [Related]
7. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
10. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
11. The pathway to pyrimidines: The essential focus on dihydroorotate dehydrogenase, the mitochondrial enzyme coupled to the respiratory chain.
Löffler M; Carrey EA; Knecht W
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1281-1305. PubMed ID: 32043431
[TBL] [Abstract][Full Text] [Related]
12. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides.
Löffler M; Jöckel J; Schuster G; Becker C
Mol Cell Biochem; 1997 Sep; 174(1-2):125-9. PubMed ID: 9309676
[TBL] [Abstract][Full Text] [Related]
13. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
16. On dihydroorotate dehydrogenases and their inhibitors and uses.
Munier-Lehmann H; Vidalain PO; Tangy F; Janin YL
J Med Chem; 2013 Apr; 56(8):3148-67. PubMed ID: 23452331
[TBL] [Abstract][Full Text] [Related]
17. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
18. The Warburg effect modulates DHODH role in ferroptosis: a review.
Amos A; Amos A; Wu L; Xia H
Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
[TBL] [Abstract][Full Text] [Related]
19. Partial inhibition of mitochondrial-linked pyrimidine synthesis increases tumorigenic potential and lysosome accumulation.
Desler C; Durhuus JA; Hansen TL; Anugula S; Zelander NT; Bøggild S; Rasmussen LJ
Mitochondrion; 2022 May; 64():73-81. PubMed ID: 35346867
[TBL] [Abstract][Full Text] [Related]
20. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
